In their totality, our data indicate the potential role of LGR5 both as a prognostic tool to determine malignant DCIS lesions alongside the value of utilizing LGR5 to stratify ER+ and ER− BC tumor grade and recurrence (Fig. 6). Here, ESR1 is linked to ductal breast carcinoma in situ.